Skip to content

A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold

Efficacy and Safety of an Antiviral Polymeric Nasal Spray: A Randomized, Parallel Group, Double-blind, Placebo-controlled Study in Subjects With Early Symptoms of Common Cold

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01488604
Enrollment
163
Registered
2011-12-08
Start date
2012-01-31
Completion date
2012-05-31
Last updated
2012-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Cold

Brief summary

This study will test 200 people to see if an experimental nasal spray has an effect on symptoms of the common cold if used when the symptoms start. At the first visit to the clinic, potential subjects will have tests to make sure they qualify to participate in the study. If they qualify, they will have an equal chance of receiving the experimental nasal spray or a sham nasal spray (one that does not have the experimental formula). At the first visit, subjects will receive their assigned nasal spray and use it once at the clinic. They will also receive a booklet called a diary. Subjects will take the rest of their treatments for day 1 at home, and for the next six days, they will use the nasal spray four times per day and record their symptoms in the diary, as instructed. Then subjects will come back to the clinic for a final visit.

Detailed description

This is an investigation in healthy subjects with early signs of common cold. Subjects will be randomly assigned in a 1:1 ratio to receive either Polymeric Nasal Spray or a matching placebo nasal spray. Subjects will be screened for eligibility and randomized to treatment at the Screening/ Randomization Visit (Day 1). Subjects will apply the first dose of the nasal spray at this visit under supervision. The other applications will take place at home on Day 1. On Days 2 through 7, subjects will use their assigned nasal spray as 2 sprays per nostril, 4 times per day. One Follow up Visit will be conducted within 3 days of the last application of nasal spray. Enrollment will continue until 200 subjects have completed the investigation (100 per treatment group). The subject and the investigative staff will be blinded to the assigned nasal spray. Efficacy will be measured, and recorded in the subject's diary, and safety will be assessed by reported AEs and ADEs.

Interventions

DEVICEPolymeric Nasal Spray

Experimental nasal spray

DEVICESham Nasal Spray

Sham nasal spray

Sponsors

McNeil AB
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have early signs of a common cold: If female of child-bearing potential, have a negative pregnancy test at Screening. * Have signed and dated the informed consent document, indicating that they have been informed of all pertinent aspects of the investigation * Are willing and able to comply with scheduled visits, treatment plan, and other investigation procedures

Exclusion criteria

* Have had common cold or flu-like symptoms outside the protocol-specified parameters. * Are current smokers as defined by the protocol. * Have any medical history or condition or use any drug or device that (per protocol or in the opinion of the investigator) might compromise subject safety, participation in the trial, action of the investigational device, or results of the investigation.. * Are related to anyone involved with the conduct of the investigation.

Design outcomes

Primary

MeasureTime frameDescription
Symptoms of the Common ColdWithin 7 daysSubjects will score their symptoms of the common cold including local symptoms (sore throat, blocked nose, runny nose, cough, and sneezing) and systemic symptoms (headache, muscle ache, and chilliness) on a scale of 0-3, where 0=: None (symptoms not present in the previous 24 hours) and 3= Severe (symptoms disturbing/irritating most of the time).

Secondary

MeasureTime frameDescription
Effect of Common Cold on Daily ActivitiesWithin 7 daysSubjects will score how their cold affects daily activities on a scale of 0-3, where 0= None (able to carry out daily activities as normal) and 3= Severe (very limited or no ability to carry out daily activities).
Effect of Common Cold Symptoms on SleepWithin 7 daysSubjects will score how their cold affects ability to sleep on a scale of 0-3, where 0= None (no effect on sleep) and 3= Severe (sleep severely affected, or sleep not possible).
Number of Days LostWithin 7 daysThe number of days lost at school or work because of the common cold will be recorded in the subject diary.
Treatment OutcomeWithin 7 daysTreatment outcome will be recorded by the subject on the evenings of treatment days on a scale of 0-4, where 0=Complete recovery and 4=Deterioration.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026